Research programme: therapeutic antibodies - Pfizer/BioWa/Lonza

Drug Profile

Research programme: therapeutic antibodies - Pfizer/BioWa/Lonza

Latest Information Update: 02 Aug 2013

Price : $50

At a glance

  • Originator Pfizer
  • Class Antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 30 Jul 2013 Early research in Undefined indication in USA (unspecified route)
  • 30 Jul 2013 BioWa and Lonza enter into research and commercialisation agreements with Pfizer for use of their technology for therapeutic antibody research and development at Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top